I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment
I-Mab's givastomig is a unique immune-boosting drug for stomach cancer, expected to outperform competitors, according to Leerink.
NOTRELOAD AI
Rumble and Perplexity Team Up for Smarter Video Discovery
Rumble now uses Perplexity AI to help you find the best videos easily. Includes a new subscription bundle and promotion for the Comet browser.
Applied Materials Forecasts $600M Revenue Hit from Expanded China Export Curbs
Applied Materials expects a $600 million revenue loss in fiscal 2026 due to new U.S. rules restricting exports of chip manufacturing machinery to China-based affiliates aimed at preventing circumvention of controls.
U.S. FDA Approves Jazz's Combination Therapy for Lung Cancer
The FDA approved the Zepzelca/Tecentriq drug combo as a maintenance treatment for advanced small cell lung cancer.
Uber Boosts AI Business by Buying Segments.ai
Uber bought Segments.ai, a startup, to expand its AI data-labeling unit. They train self-driving tech and now serve over 50 clients.
Gene Therapy Showdown: Taysha's Speed vs. Neurogene's Durability
A look at why analysts are favoring Neurogene over Taysha in the race for gene therapy approvals, focusing on study design, FDA alignment, and long-term patient outcomes.